Midatech Pharma : Description Report of Foreign Issuer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of, June 2019

Commission File Number 001-37652

Midatech Pharma PLC

(Translation of registrant's name into English)

Oddfellows House,

19 Newport Road,

Cardiff, CF24 0AA, United Kingdom(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-Fx Form 40-Fo

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

SUBMITTED HEREWITH

Attached to the Registrant's Form 6-K filing for the month of June 2019, and incorporated by reference herein, is:

Exhibit No.		Description
99.1		Press release, dated June 19, 2019 entitled "Result of AGM."

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Midatech Pharma PLC

Date: June 19, 2019

By:

/s/ Nicholas Robbins-Cherry

Nicholas Robbins-Cherry

Chief Financial Officer

		Exhibit Index
Exhibit No.		Description
99.1		Press release, dated June 19, 2019 entitled "Result of AGM."

Exhibit 99.1

19 June 2019

Midatech Pharma PLC

("Midatech" or the "Company")

Result of AGM

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that all resolutions were passed at the Annual General Meeting held earlier today.

For more information, please contact:

Midatech Pharma PLC

Dr Craig Cook, CEO

Tel: [phone]

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Tel: [phone]

IFC Advisory Limited (Financial PR and UK Investor Relations)

Graham Herring / Tim Metcalfe / Heather Armstrong

Tel: [phone]

Email: [e-mail]

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: [phone]

Email: [e-mail]

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

The Company has developed three in house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies are into the clinic:

• Q-Sphera™platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).